2026 Outlook

2026 marks a defining year on the path to Vision 2030 with three strategic priorities:

Impact more patients globally with VYVGART, driving broader adoption across current patient populations and unlocking new opportunities with potential label expansions
Shape the long-term future of FcRn medicines, advancing future FcRn molecules, innovative delivery modalities and combination approaches designed to transform patient outcomes
Deliver next wave of immunology innovation, accelerating empasiprubart and diversified pipeline of first-in-class molecules to drive sustainable value creation

12-18 Month Catalyst Outlook

Seronegative gMG FDA decision on approval expected on May 10, 2026
Registrational clinical trial in Graves’ disease expected to initiate in 2026 
adimanebart CMS registrational clinical trial on track to start in third quarter of 2026
ARGX‑213 expected to enter patient clinical trials in 2026
ARGX‑124 expected to complete Phase 1 by end of 2026 
ARGX‑121 Phase 2 in IgA nephropathy expected to start in 2026 
Three new molecules expected to enter Phase 1 in 2026: ARGX‑118, ARGX‑125, TSP‑101